Navigation Links
Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection

Sangamo BioSciences, Inc. today announced that data from its program to develop a ZFP Therapeutic for HIV/AIDS were presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. The study represents the first demonstration that cells can be made resistant to HIV infection by treatment with Sangamo's proprietary zinc finger DNA-binding protein nucleases (ZFNTM) designed to specifically disrupt the CCR5 gene.

In its anti-HIV preclinical research program, Sangamo has designed ZFNs that can be used to disrupt the CCR5 gene, a receptor required for HIV entry into immune cells. The researchers found that ZFN-modified cells were resistant to HIV infection whereas control cells were infected when challenged with the virus. Furthermore, when CCR5 expression was experimentally restored in the ZFN-modified cells, HIV was once again able to infect these cells. Sangamo has shown disruption of the CCR5 gene in a number of different cell types including T-cells, the target cell for this therapeutic approach.

"CCR5 is an important target in the fight against HIV/AIDS," stated Edward Lanphier, Sangamo's president and CEO. "Individuals with a natural mutation of their CCR5 gene have been shown to be resistant to HIV infection. Several major pharmaceutical companies have initiated programs to develop small molecule drugs to block HIV binding to CCR5, but in recent months two trials have been halted, one due to reports of liver toxicity of the candidate drug. We believe that using ZFNs to permanently modify the CCR5 gene specifically in T-cells and thus directly block the expression of the protein on the surface of these cells may have several advantages over the systemic effects of other drugs in development."

Small molecule or antibody approaches require the constant presence of antagonist in high enough concentrations to block therapeutically relevant numbers of the CCR5 protein, of which there
'"/>

Source:jjackson@burnsmc.com


Page: 1 2

Related biology news :

1. MRSA study demonstrates need for frequent hand washing and environmental disinfection in health care settings
2. New research demonstrates bone-marrow derived stem cells can reverse genetic kidney disease
3. Xie Lab demonstrates the role of microRNA pathway
4. Protein discovery could unlock the secret to better TB treatment
5. Topical treatment shown to inhibit HIV and herpes simplex virus infection
6. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
7. Researchers add new tool to tumor-treatment arsenal
8. Potential treatments for neurofibromatosis
9. Nanoparticles offer new hope for detection and treatment
10. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
11. PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment
Post Your Comments:
(Date:2/25/2015)... 25, 2015  ABC Financial Services (ABC), the ... Health and Fitness Industry, today announced enhancements to ... The latest upgrade includes advances to the agreement ... check-in via Identity One fingerprint biometrics. The features ... interactive displays at the International Health, Racquet & ...
(Date:2/24/2015)... Feb. 24, 2015 This report analyzes the worldwide markets ... Segments: Face Biometrics, and Voice Biometrics. The report provides separate comprehensive ... Japan , Europe , Asia-Pacific ... Africa , and Latin America . Annual ... Also, a seven-year historic analysis is provided for these markets. Market ...
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... can skim through certain kinds of damaged DNA without ... performed in bacteria, suggest a new mechanism that can ... results were published online this week in the ... senior author is Paul Doetsch, PhD, professor of biochemistry ...
... from the Hood Center for Children and Families at Dartmouth ... the significant potential negative impact that food product placements in ... which appears in the current edition of the journal ... food, beverage, and food retail establishments that are frequently portrayed ...
... at Barrow Neurological Institute at St. Joseph,s Hospital and ... of a new category of painkillers, called TRPV1 antagonists. ... vannilloid-1 (TRPV1) channel, which is the same receptor responsible ... clinical trials have revealed that TRPV1 antagonists cause hyperthermia- ...
Cached Biology News:Cells can read damaged DNA without missing a beat 2New study examines the impact on children of food product placements in the movies 2New study examines the impact on children of food product placements in the movies 3New era of pain drugs advanced by Barrow researcher 2
(Date:3/5/2015)... e2b teknologies , a premier ... Northeast Ohio, today announced a leading independent multi-specialty physician ... upgrade to the latest version of Sage 100 ... of its kind in the region, the organization has ... so efficiency and data accessibility are paramount to their ...
(Date:3/5/2015)... RMI specializes in ... conditions such as meniscal tears, ACL injuries, rotator ... pain due to degenerative conditions like osteoarthritis. ... to promote better post-surgical outcomes. , Stemnexa combines ... bone marrow harvesting with two complimentary cellular technologies: ...
(Date:3/4/2015)... , March 4, 2015 In an article ... UPMC Center for Health Security review the clinical aspects ... be used as bioweapons. The article, "Clinical Management of ... on the website of the New England Journal ... Eric Toner , and Tom Inglesby—review the clinical ...
(Date:3/4/2015)... BROOKLYN, N.Y. , March 4, 2015  Brooklyn ... treat their acute and chronic pain and injuries. ... to announce the grand opening of his NJS Physical ... NY on Thursday, March 5, 2015. Health ... the facility, which is located at 1178 Flatbush Avenue. ...
Breaking Biology Technology:Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5Latest Clinical Information On Bioterrorism Threats 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... Dalton Medicinal Chemistry Partners,the Medicinal Chemistry arm ... achieved a targeted milestone in its Medicinal ... milestone achievement triggered,payment of an undisclosed amount. ... their medicinal,chemistry expertise to design and synthesize ...
... LOS ANGELES, Calif., Oct. 29 Elekta, ... neurosurgery solutions, announced,Elekta Infinity*, the definitive new ... Modulated Arc Therapy* (VMAT), a very,fast Intensity ... or multiple arcs, at the 49th Annual ...
... Puerto Rico and CORONA, Calif., Oct. 29 ... Pharmaceuticals, Inc. announced,today that under a supply ... Watson has launched Tilia(TM) Fe (norethindrone acetate ... tablets), the generic,version of Warner Chilcott,s oral ...
Cached Biology Technology:Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors 2Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors 3Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe 2Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe 3Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe 4
CBF-B (G-2)...
Mouse monoclonal [164-12-2] to Ampicillin ( Abpromise for all tested applications)....
Flotillin-2 (ESA) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 29, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
... Product Rabbit polyclonal to Kv4.2 ... to KLH, corresponding to amino acids 23-43 ... Cross-reacts with Rat.Expected to cross-react with ... identity with immunogen), Rabbit (100% identity with ...
Biology Products: